This AI trading robot "Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)", was one of the best in our robot factory, generating a 7.12% gain for OCGN over the course of the previous week.
As per the technical analysis, the Stochastic Oscillator for OCGN moved out of oversold territory on April 13, 2023, which could indicate a shift from a downward trend to an upward trend. This may be considered a bullish signal for traders who may want to buy the stock or buy call options.
Tickeron's A.I.dvisor analyzed 79 instances where the Stochastic Oscillator left the oversold zone and found that in 73 of those cases, the stock price moved higher in the following days. This gives a probability of over 90% for a continued upward trend in the case of OCGN.
However, traders should also consider other factors such as market conditions, company news, and earnings reports before making any investment decisions. It's important to note that short-term gains may not necessarily be sustainable in the long run. Therefore, it's crucial to conduct thorough research and analysis before making any investment decisions.
Day Trader: Medium Volatility Stocks for Active Trading (TA&FA)
OCGN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on April 11, 2024. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The 10-day RSI Indicator for OCGN moved out of overbought territory on April 09, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The 10-day moving average for OCGN crossed bearishly below the 50-day moving average on May 01, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for OCGN entered a downward trend on April 30, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 75 cases where OCGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on May 02, 2024. You may want to consider a long position or call options on OCGN as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
OCGN moved above its 50-day moving average on April 26, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where OCGN advanced for three days, in of 222 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OCGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.439) is normal, around the industry mean (10.296). P/E Ratio (0.000) is within average values for comparable stocks, (116.129). OCGN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.466). OCGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (53.763) is also within normal values, averaging (233.055).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development and commercialization of therapies for eye diseases
Industry Biotechnology